Category Archives: Blog

Working together to combat coronavirus

The World Health Organization (WHO) recently declared the outbreak of 2019-nCoV, a novel strain of coronavirus that originated in Wuhan, China, a global health emergency. In the last three weeks, the number of confirmed cases has risen from about 50 in China to nearly 25,000 in 25 countries. Administration officials here in the United States have taken […]

ICYMI: Continued biopharmaceutical action on COVID-19

Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a disease caused by a novel strain of coronavirus. Daniel O’Day of Gilead Sciences, Julie Louise Gerberding, M.D., M.P.H. of Merck & Co., Inc, Paul Stoffels, […]

ICYMI: America’s biopharmaceutical companies are taking on COVID-19

The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial contributions and collaboration with public partners. Several PhRMA member companies are advancing discovery efforts for vaccine candidates and collaborating across the industry to share existing technologies that can […]

Guest post: Looking out for the invisibly vulnerable in the time of COVID-19

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Dr. Doug Williamson, […]

New infographic: How we are fighting COVID-19

America’s biopharmaceutical companies have joined forces to fight COVID-19. Armed with experience garnered from previous outbreaks and a vast storehouse of knowledge about infectious diseases like influenza, malaria and HIV, researchers are working to develop and deliver diagnostics, treatments and vaccines to save lives and restore the rhythms of daily life for billions of people. […]

Guest post: Securing the health care supply chain during COVID-19

Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Nicolette Louissaint, Ph.D., […]

New report shows nearly 260 vaccines in development, including dozens for COVID-19

Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most devastating conditions. There are several notable success stories in prevention of infectious diseases in the U.S. and worldwide. Smallpox at one point was […]

Observing National Minority Health Month in the age of COVID-19

Every April, National Minority Health Month is observed. The month is dedicated to continuing to raise awareness about health disparities affecting racial and ethnic minority groups. Each year, briefings highlighting the latest statistics are held, panels discussing next steps to improve underlying social determinants of health are convened and researchers, public health experts and community […]

Helping those affected by the coronavirus

America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus. In addition to applying their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and […]